Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$86.72 USD

86.72
4,365,080

-0.64 (-0.73%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

J&J (JNJ) Seeks FDA Approval for Myeloma Drug Teclistamab

J&J (JNJ) submits a Biologics License Application, seeking approval for its bispecific antibody candidate teclistamab as a treatment option for the heavily pretreated multiple myeloma patients.

Zacks Investment Ideas feature highlights: Gilead Sciences, Regeneron and Avid Bioservices

Zacks Investment Ideas feature highlights: Gilead Sciences, Regeneron and Avid Bioservices

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $73.64, marking a +0.92% move from the previous day.

GILD or VIR: Which Is the Better Value Stock Right Now?

GILD vs. VIR: Which Stock Is the Better Value Option?

Biotech Stock Roundup: Regulatory Updates From NVAX, BBIO Down on Drug Failure & More

Regulatory and other pipeline updates from NVAX and BBIO are among a few key highlights from the biotech sector during the past week.

Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

Here is how Gilead Sciences (GILD) and GlaxoSmithKline (GSK) have performed compared to their sector so far this year.

Gilead (GILD) Hits Fresh High: Is There Still Room to Run?

Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Can Veklury Sales Retain Momemtum for Gilead (GILD) in 2022?

Solid sales from Veklury cushion Gilead (GILD) in 2021 amid COVID-19. However, new oral antivirals in the market might hurt sales. GILD now shifts focus to oncology as the virology space faces issues.

Ligand (LGND) Stock Surges 60% YTD: What's Driving the Rally?

Strong demand for two of Ligand's (LGND) partnered drugs, AMGN's Krprolis and GILD's Veklury, is driving its royalties. This is likely to continue next year.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $72.48, moving +0.07% from the previous trading session.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $72.43, moving +0.82% from the previous trading session.

Biotech Stock Roundup: Regulatory Updates From BIIB, AMGN and NVAX & More

Regulatory and other pipeline updates from Biogen (BIIB) and Novavax (NVAX) have been the biotech sector's few key highlights during the past week.

Gilead's (GILD) Veklury Gets EC Nod for Use in Early COVID-19

Gilead's (GILD) Veklury can now be used in the EU at the early stages of COVID-19 to help prevent disease progression in high-risk patients.

Vir (VIR), Glaxo's Xevudy Wins EC Approval for COVID-19

Vir Biotechnology, Inc. (VIR) and partner GlaxoSmithKline obtain the European Commission's nod for Xevudy for the early treatment of COVID-19.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $72.31, moving +1.54% from the previous trading session.

Merck's (MRK) HIV Studies on Islatravir Put on Clinical Hold

With the FDA's clinical hold, no new studies can be initiated on Merck's (MRK) islatravir. While six studies on islatravir have been placed on full clinical hold, seven have been put on partial clinical hold.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $70.25, moving -0.07% from the previous trading session.

Merck (MRK) Pauses Enrolment in HIV-1 Prevention Studies

Merck (MRK) pauses enrolment for two phase III studies evaluating islatravir for pre-exposure prophylaxis of HIV-1 infection, following the recommendation of an external data monitoring committee.

Amazon's (AMZN) AWS Gets Selected by Gilead, Boosts Clientele

Amazon's (AMZN) AWS is chosen by Gilead Sciences as the preferred cloud provider.

The Zacks Analyst Blog Highlights: Accenture, Raytheon, Becton, Dickinson and Co, Boeing and Gilead Sciences

The Zacks Analyst Blog Highlights: Accenture, Raytheon, Becton, Dickinson and Co, Boeing and Gilead Sciences

Mark Vickery headshot

Top Analyst Reports for Accenture, Raytheon & Becton, Dickinson

Today's Research Daily features new research reports on 16 major stocks, including Accenture plc (ACN), Raytheon Technologies Corporation (RTX), and Becton, Dickinson, and Company (BDX).

Ligand's (LGND) Drug-Developing Technologies Holds Potential

Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.

Gilead Sciences (GILD) Stock Gains 20% YTD: What Lies Ahead?

Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.